



## UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
UNITED STATES PATENT AND TRADEMARK OFFICE  
WASHINGTON, D.C. 20231  
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/780,438	02/09/2001	Xiaoyang Qi	

CONFIRMATION NO. 7718

## FORMALITIES LETTER



\*OC000000007920253\*

FROST BROWN TODD LLC  
2200 PNC Center  
201 East Fifth Street  
Cincinnati, OH 45202-4182

Date Mailed: 04/22/2002

### NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov


*A copy of this notice **MUST** be returned with the reply.*

Customer Service Center  
Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE

75-02-02

06360  
#8



23

PATENT

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

In re application of:

Applicants Xiaoyang Qi

: Paper No:

Serial No. 09/780,438

: Group Art Unit: 1615

Filed: February 9, 2001

: Examiner:

For: FUSOGENIC PROPERTIES OF SAPOSIN C AND RELATED PROTEINS  
AND POLYPEPTIDES FOR APPLICATION TO TRANSMEMBRANE  
DRUG DELIVERY SYSTEM

RESPONSE

THE ASSISTANT COMMISSIONER FOR PATENTS  
Washington, D.C. 20231

Dear Sir:

In response to the Office Action, dated April 22, 2002, please consider the following remarks.

Attached hereto, as requested by the Examiner, is the corrected sequence listing for the above patent application, revised to comply with 37 CFR 1.821 - 1.825. A computer-readable diskette, which contains the sequence listing in ASCII format is also enclosed, along with a written sequence listing which is identical to the electronic sequence listing. These sequence listings correspond to the sequence listings contained in the above-cited application and as such, no new matter is introduced as a result of these corrections.

Respectfully submitted,

XIAOYANG QI, PH.D.

*Karlyn A. Schnapp*

Karlyn A. Schnapp

Registration No. 45,558

Attorney for Applicant

Telephone (513) 651-6865

FROST BROWN TODD, LLC


2200 PNC Center

201 East Fifth Street

Cincinnati, Ohio 45202-4182

Dated: April 30, 2002

Serial No. 09/780,438



**CERTIFICATE OF MAILING**

I hereby certify that a copy of this correspondence is being deposited with the United States Postal Service as EXPRESS MAIL in an envelope addressed to The Assistant Commissioner of Patents, Washington, D.C. 20231 this 30<sup>th</sup> day of April, 2002.

  
Karen Kruetzkamp

CINlibrary/1175235.1